 Rectally absorbable form of L-dopa |
| What is claimed is: 1. A pharmaceutical composition for enhancing rectal absorption of L-dopa by ... |
|
| Method to treat Parkinsons disease |
| I claim: 1. The method of treatment of Parkinson's disease and related neurological syndromes which ... |
|
| Method of using cytoprotective alcohols to treat neural disease and neural injury |
| The present invention is grounded in the surprising discovery that hexacosanol and analogues and ... |
|
| Methods of treating Parkinson's disease using melanin |
| OF THE INVENTION One aspect of the present invention relates to the treatment of a mammal having a ... |
|
| Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds |
| OF THE INVENTION The present invention thus provides as a novel compound the R(+)-enantiomer of N-... |
|
| L-DOPA ethyl ester to treat Parkinson's disease |
| OF THE INVENTION This invention provides a composition which comprises a pharmaceutically ... |
|
| Episomal vector systems and related methods |
| The present invention provides papilloma virus episomal vector systems and methods for papilloma ... |
|
| Method for treating Parkinson's disease employing an ATP-sensitive potassium channel blocker |
| What is claimed is: 1. A method for treating Parkinson's disease, which comprises administering ... |
|
| Method of treatment of parkinson's disease |
| We claim: 1. A method of treatment of Parkinson's disease in a patient in need of such treatment, ... |
|
| 4-aminoethoxy indolone derivatives |
| What is claimed is: 1. A compound of the formula I: ##STR5## in which: Y is hydrogen, halogen or ... |
|
|
Crosslinked polymer compositions and methods for their use
| Details |
Inventors: Rhee, Woonza M.; DeLustro, Frank A.; Berg, Richard A.;
Assignee: Cohesion Technologies, Inc. (Palo Alto, CA)
Primary Examiner: Nutter; Nathan M.
Assistant Examiner:
Attorney, Agent or Firm: Foley & Lardner, Axford; Laurie A.
Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (--NH.sub.2) or thiol (--SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant. |
|
DETAILED DESCRIPTION The present invention discloses a crosslinked polymer composition comprising a first synthetic polymer containing two or more nucleophilic groups, and a second synthetic polymer containing two or more electrophilic groups which are capable of covalently bonding to one another to form a three dimensional matrix.
A preferred composition of the invention comprises polyethylene glycol containing two or more primary amino groups as the first synthetic polymer, and polyethylene glycol containing two or more succinimidyl groups (a five-membered ring structure represented herein as --N(COCH.
sub.
2).
sub.
2) as the second synthetic polymer.
In a general method for preparing a composition for the delivery of a negatively charged compound (such as a protein or drug), a first synthetic polymer containing two or more nucleophilic groups is reacted with a second synthetic polymer containing two or more electrophilic groups, wherein the first synthetic polymer is present in molar excess in comparison to the second synthetic polymer, to form a positively charged matrix, which is then reacted with a negatively charged compound.
In a general method for preparing a matrix for the delivery of a positively charged compound, a first synthetic polymer containing two or more nucleophilic groups is reacted with a second synthetic polymer containing two or more electrophilic groups, wherein the second synthetic polymer is present in molar excess in comparison to the first synthetic polymer, to form a negatively charged matrix, which is then reacted with a positively charged compound.
In a general method for effecting the nonsurgical attachment of a first surface to a second surface, a first synthetic polymer containing two or more nucleophilic groups is mixed with a second synthetic polymer containing two or more electrophilic groups to provide a reaction mixture; the reaction mixture is applied to a first surface before substantial crosslinking has occurred; and the first surface is contacted with a second surface to effect adhesion between the two surfaces
|
| Related patents |
|
|
Conjugation of polypeptides
OF THE INVENTION It is the object of the invention to provide polypeptide conjugates with reduced allergenicity. As described above it is well-known according to prior ...
|
|
|
High molecular weight polymer-based prodrugs
OF THE INVENTION A. THE PRODRUGS In most aspects of the invention, the prodrug compositions of the present invention contain hydrolyzable linkages between the polymer ...
|
|
|
Non-antigenic amine derived polymers and polymer conjugates
In one aspect of the invention, there are provided amine-based polymer intermediates having the formula: R--B (I) wherein (R) is a water-soluble, substantially non-...
|
|
|
Biodegradable high molecular weight polymeric linkers and their conjugates
The present invention includes compounds of the formula: (D).sub.n --M--(R.sub.1).sub.m (I) wherein (m) and (n) independently selected positive integers, preferably from ...
|
|
|
Modified polypeptides with high activity and reduced allergenicity
OF THE INVENTION The modified polypeptide of the present invention is represented by the formula: A-B.sub.n containing, as essential components, a enzyme, A, and a ...
|
|
|
Poly(ethylene glycol) derivatives with proximal reactive groups
OF THE INVENTION The terms "group," "functional group," "moiety," "active moiety," "reactive site," reactive group" and "reactive moiety" are used in the art and herein ...
|
|
|
Devices for cloaking transplanted cells
A variety of devices can be used to contain or cloak a source of a therapeutic substance, often cells, which source provides the substance to a host or recipient subject....
|
|
|
Terminally-branched polymeric linkers and polymeric conjugates containing the same
In one aspect of the invention, compounds of Formula (I) are provided: ##STR6## wherein: J is ##STR7## E.sub.1-4 are independently selected from the group consisting of ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising rectally administering to a patient a ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising a therapeutically effective dosage amount of an ...
|
|
|
Gene Therapy 
